Trials / Completed
CompletedNCT00214604
Type III Dysbetalipoproteinemia
An 18-week, Randomized, Multicenter, Phase 3b, Double-blind, Crossover Study, Followed by an 18-week Open-Label Period to Evaluate the Efficacy & Safety of the Lipid-Regulating Agents, Rosuvastatin & Pravastatin in the Treatment of Subjects With Dysbetalipoproteinemia (Frederickson Type III Hyperlipoproteinemia)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the efficacy of rosuvastatin 10mg, rosuvastatin 20mg and pravastatin 40mg in subjects with dysbetalipoproteinemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin | 10mg |
| DRUG | rosuvastatin | 20mg |
| DRUG | pravastatin | 40mg |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2007-02-01
- Completion
- 2007-02-01
- First posted
- 2005-09-22
- Last updated
- 2010-11-19
Locations
2 sites across 2 countries: Norway, South Africa
Source: ClinicalTrials.gov record NCT00214604. Inclusion in this directory is not an endorsement.